Last Updated: May 20, 2026

PRAVASTATIN Drug Patent Profile

Name: PRAVASTATIN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Pravastatin, and what generic alternatives are available?

Pravastatin is a drug marketed by Accord Hlthcare, Apotex, Aurobindo Pharma, Aurobindo Pharma Usa, Biocon Pharma, Chartwell Rx, Cipla, Dr Reddys Labs Inc, Glenmark Pharms Ltd, Hisun Pharm Hangzhou, Pharmobedient, Pliva Hrvatska Doo, Ranbaxy Labs Ltd, Senores Pharms, Watson Labs, and Zydus Pharms Usa. and is included in eighteen NDAs.

The generic ingredient in PRAVASTATIN is pravastatin sodium. There are sixteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the pravastatin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pravastatin

A generic version of PRAVASTATIN was approved as pravastatin sodium by AUROBINDO PHARMA USA on April 24^th, 2006.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for PRAVASTATIN?
What are the global sales for PRAVASTATIN?
What is Average Wholesale Price for PRAVASTATIN?

Summary for PRAVASTATIN

US Patents:	0
Applicants:	16
NDAs:	18
Drug Prices:	Drug price information for PRAVASTATIN
Drug Sales Revenues:	Drug sales revenues for PRAVASTATIN
DailyMed Link:	PRAVASTATIN at DailyMed

Drug patent expirations by year for PRAVASTATIN

US Patents and Regulatory Information for PRAVASTATIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	PRAVASTATIN SODIUM	pravastatin sodium	TABLET;ORAL	079187-001	May 27, 2010		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Dr Reddys Labs Inc	PRAVASTATIN SODIUM	pravastatin sodium	TABLET;ORAL	076714-004	Dec 28, 2007	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pliva Hrvatska Doo	PRAVASTATIN SODIUM	pravastatin sodium	TABLET;ORAL	077730-002	Nov 21, 2006		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for PRAVASTATIN

How do manufacturers production costs affect pravastatin's price?
How significant is the otc pravastatin price drop from lipitor?
Is pravastatin more cost effective than lipitor for high cholesterol?
Can i buy pravastatin over the counter?
Is pravastatin available over the counter?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.